As 3D printing drugs in rural hospitals becomes a reality, what are the opportunities and threats for AstraZeneca?

In rural hospitals, critical drugs are often not in stock. Desperate patients and their families are further pushed into prolonged suffering. Feeling they have nothing to lose, some resort to DIY solutions.

As additive manufacturing is applied to drug production at patients’ closest point of sale, we can imagine a world where rural patients purchase out-of-stock drugs within a few hours of visiting a local hospital. What if the hospital had a 3D printer? What if CAD files from global pharmaceutical companies like AstraZeneca were available?

Digitalization in the pharmaceutical industry: Pfizer

Posted on

With the advent of digitalization, the pharmaceutical industry is using information sharing to improve its manufacturing and supply chain efficiency. Pfizer’s creation of the PCMM plant is one way manufacturing may change in addition to gathering provider-level, and perhaps even patient-level, information. But can providers and patients trust Pfizer and other members of the pharmaceutical industry with their data?

How digitization of pharma R&D can decrease supply chain costs

Posted on

Sourcing comparator drugs for pharma research and development process is expensive and there is high risk of receiving a counterfeited drug from a third-party supplier. To reduce these adverse effects, TransCelerate Biopharma started Comparator Network Initiative to introduce a digital platform where companies can source drugs for each other in a safe a quick way.